The wearable technology market has produced many category-defining products — the step counter, the heart rate monitor, the sleep tracker. But few wearable technologies have generated as much enthusiasm, controversy, and genuine scientific interest as the continuous glucose monitor (CGM) used by people without diabetes.
CGMs — small sensors inserted under the skin that measure interstitial glucose levels every 1-5 minutes — were developed for Type 1 and Type 2 diabetes management, where real-time glucose data is clinically essential. But over the past five years, a parallel market has emerged: non-diabetic individuals — biohackers, athletes, functional medicine patients, and health-curious consumers — wearing CGMs to understand their metabolic responses to food, exercise, stress, and sleep.
Companies like Levels, Nutrisense, Signos, and January AI have built consumer businesses around this concept, packaging CGM sensors (manufactured by Abbott and Dexcom) with software platforms that interpret and gamify the glucose data. The promise: personalized metabolic insights that will optimize your diet, energy, and long-term health.
But what does the evidence actually support? And what are the limitations of applying diabetic technology to non-diabetic physiology?
How CGMs work
A CGM sensor consists of a tiny filament inserted into the subcutaneous tissue of the upper arm or abdomen. This filament measures glucose concentration in the interstitial fluid (the fluid between cells) — which closely tracks blood glucose but with a 5-15 minute lag. The sensor transmits data wirelessly to a smartphone app, producing a continuous glucose trace — a "glucose curve" — that reveals exactly how your blood sugar responds to every meal, workout, stressor, and night of sleep.
The technology is remarkable — replacing the single-point-in-time snapshot of a fasting blood glucose test with a 24/7 data stream that captures the dynamic reality of glucose metabolism.
What CGMs reveal in non-diabetic users
Glycemic variability
The most striking finding when healthy people wear CGMs is the degree of glycemic variability — blood sugar fluctuations that are invisible on standard fasting blood tests. Two people eating identical meals can produce dramatically different glucose responses — differences driven by genetics, gut microbiome composition, sleep quality, stress levels, exercise timing, and meal composition.
The landmark 2015 Weizmann Institute study (Zeevi et al., Cell) demonstrated this personalized glycemic response: standardized meals produced glucose responses that varied by up to 4x between individuals. Some participants spiked dramatically after white bread but not after chocolate cake; others showed the opposite pattern.
Postprandial glucose patterns
CGM data reveals four general postprandial (post-meal) glucose patterns in non-diabetics: minimal response (glucose rises <20 mg/dL — the metabolically efficient pattern), moderate spike and recovery (glucose rises 20-40 mg/dL and returns to baseline within 1-2 hours — normal), large spike and recovery (glucose rises 40-60+ mg/dL but returns to baseline — a potential early sign of insulin resistance), and large spike with delayed recovery (glucose rises >60 mg/dL and takes >2 hours to return to baseline — suggestive of significant insulin resistance even if fasting glucose is normal).
The dawn phenomenon
Many CGM users observe elevated morning glucose — the "dawn phenomenon" — caused by cortisol-mediated hepatic glucose output in the early morning hours. This is physiologically normal (the body is preparing for waking activity) but can be pronounced in individuals with insulin resistance.
What the evidence supports
For diabetics (strong evidence)
CGM use in Type 1 and Type 2 diabetes is well-supported by evidence: improved HbA1c, reduced hypoglycemia, better time-in-range, and improved quality of life. CGMs are standard of care for insulin-dependent diabetes.
For pre-diabetes (moderate evidence)
For individuals with pre-diabetes (fasting glucose 100-125 mg/dL or HbA1c 5.7-6.4%), CGM use has emerging evidence: real-time glucose feedback can motivate dietary changes, CGM data can identify specific food triggers that standard testing misses, and behavioral intervention guided by CGM data may improve glycemic parameters.
For healthy individuals (limited evidence)
For metabolically healthy individuals (normal fasting glucose, normal HbA1c, no insulin resistance), the evidence for CGM use is limited and primarily theoretical: there are no long-term RCTs demonstrating that CGM use in healthy individuals improves hard clinical outcomes (diabetes incidence, cardiovascular events, mortality), the behavioral learning hypothesis (that seeing glucose responses will drive healthier dietary choices) is plausible but unproven in rigorous studies, and the anxiety hypothesis (that constant glucose monitoring may create health anxiety in some individuals) is also plausible and understudied.
The insights that CGM provides
Despite the limited clinical trial evidence, CGM use in non-diabetics provides several genuinely useful insights:
Food response personalization. Discovering that a particular food (even a "healthy" food) produces a large glucose spike in your body — while the same food produces minimal response in someone else — is actionable personal health information.
Meal composition effects. CGM demonstrates the dramatic impact of meal composition on glucose response: protein and fat before carbohydrates blunts the glucose spike, fiber reduces glycemic variability, vinegar before meals reduces postprandial glucose, and eating carbohydrates last in a meal produces significantly smaller glucose excursions.
Exercise timing. CGM reveals that a 10-15 minute walk after meals dramatically reduces postprandial glucose spikes — more effectively than most dietary modifications.
Sleep quality impact. Poor sleep (short duration, fragmented, or delayed) produces measurably worse glucose responses the following day — CGM makes this relationship visible and motivating.
Stress visualization. Cortisol-mediated glucose elevation during stress is visible on CGM traces — providing biofeedback that can motivate stress management interventions.
The limitations
Physiological limitations
CGM measures interstitial glucose, not blood glucose — with a 5-15 minute lag. In non-diabetic ranges (70-140 mg/dL), the clinical significance of small fluctuations is uncertain. The body is designed to manage glucose dynamically — post-meal rises and returns to baseline are normal physiology, not pathology.
Psychological risks
Some users develop "glucokinesis anxiety" — excessive worry about normal glucose fluctuations that leads to food restriction, exercise compulsion, or disordered eating. The quantification of every glucose response can transform a healthy relationship with food into an anxious one.
Cost considerations
Consumer CGM programs cost $150-400 per month — a significant ongoing expense that is not covered by insurance for non-diabetic users. The cost-benefit for metabolically healthy individuals is questionable.
Who should consider CGM?
CGM use is most valuable for: individuals with pre-diabetes seeking to prevent progression to diabetes, people with a family history of Type 2 diabetes who want to understand their metabolic risk, individuals with unexplained fatigue, brain fog, or energy crashes that may be related to glucose dysregulation, athletes seeking to optimize fueling and recovery, and individuals who are motivated by data and respond well to biofeedback.
CGM use is less appropriate for: individuals with a history of or susceptibility to disordered eating, people prone to health anxiety, those who cannot afford the ongoing cost, metabolically healthy individuals who eat well and exercise regularly (where the marginal benefit of CGM data may be minimal), and children and adolescents (where the psychological risks may outweigh the benefits).
The glucose trace is a metabolic mirror. Used wisely, it reveals patterns that empower better decisions. Used anxiously, it can transform normal physiology into perceived pathology. The technology is powerful. Whether it is useful depends entirely on how you use it — and whether you need it.
The regulatory and market landscape
The consumer CGM market is evolving rapidly: the FDA approved the first over-the-counter CGM (Dexcom Stelo, Abbott Lingo) in 2024, removing the prescription requirement for non-diabetic users. This regulatory shift has opened the market to a much larger consumer base — potentially millions of health-conscious adults who want real-time metabolic data.
However, the medical community remains divided: the American Diabetes Association has not endorsed CGM use in non-diabetic populations, the Endocrine Society has expressed concern about the medicalization of normal glucose fluctuations, and some clinicians worry that consumer CGM use may increase health anxiety and unnecessary medical visits.
The market, however, is not waiting for medical consensus. Companies are investing hundreds of millions in consumer CGM platforms, and the market is projected to grow from $7 billion (2023) to $20+ billion by 2030.
The integration with other wearables
CGM data becomes dramatically more useful when combined with other wearable data: sleep tracking (correlating sleep quality with next-day glucose responses), HRV (heart rate variability — correlating autonomic nervous system function with metabolic flexibility), activity tracking (quantifying the glucose-lowering effect of specific exercise types and timing), stress monitoring (correlating perceived stress with cortisol-mediated glucose elevation), and body temperature (correlating circadian rhythm alignment with glucose regulation).
This multi-wearable integration — combining metabolic, cardiovascular, nervous system, and activity data — approaches a comprehensive real-time health monitoring system that could eventually detect disease risk before symptoms appear.
The food industry implications
CGM data has profound implications for the food industry: personalized nutrition companies are using CGM data to match individuals with optimal food choices, food companies are beginning to reformulate products based on glycemic impact data, restaurant chains may eventually provide glycemic impact information alongside calorie counts, and grocery delivery services could recommend products based on individual glucose response profiles.
The democratization of glycemic response data could fundamentally shift how food is marketed, formulated, and consumed — moving from calorie-centric to glucose-centric nutritional frameworks.
CGM and athletic performance
Athletes have adopted CGM technology to optimize performance: pre-workout fueling (ensuring adequate glucose availability without excessive hyperglycemia), during-workout fueling (maintaining glucose in optimal performance zones), recovery nutrition (optimizing glycogen replenishment timing and composition), sleep and recovery (monitoring overnight glucose stability as a recovery metric), and periodization (adjusting nutrition across training cycles based on metabolic data).
Professional cycling, triathlon, rowing, and endurance running have been early adopters — and the technology is diffusing into recreational athletics as well.
The future of metabolic monitoring
CGM technology is just the beginning of the continuous metabolic monitoring revolution. Emerging technologies include: continuous ketone monitoring (for ketogenic diet adherence and metabolic flexibility assessment), continuous lactate monitoring (for exercise physiology and performance optimization), continuous cortisol monitoring (for stress management and adrenal health), multi-analyte sensors (measuring glucose, lactate, ketones, and cortisol simultaneously), and non-invasive metabolic monitoring (optical, radiofrequency, or thermal sensing that eliminates the need for subcutaneous insertion).
These technologies will transform metabolic health from a snapshot-based discipline (annual blood tests) to a continuous, real-time monitoring paradigm — enabling early detection, personalized intervention, and proactive health management.
Making an informed decision
If you are considering CGM use, ask yourself these questions: do I have a specific metabolic concern (pre-diabetes, family history, unexplained energy fluctuations) that CGM data could address?, am I motivated by curiosity and self-optimization — or by anxiety about my health?, can I afford the ongoing cost without financial stress?, do I have access to a healthcare provider who can help me interpret the data in clinical context?, and am I prepared to see normal glucose fluctuations without interpreting them as pathology?
If you answered yes to the first and fifth questions and no to the second, CGM may be a valuable self-knowledge tool. If you answered yes to the second question, proceed with caution — or consult with a mental health professional before starting continuous monitoring.
The metabolic mirror is powerful. Used wisely, it reveals patterns that empower better decisions. Used anxiously, it transforms normal physiology into perceived pathology. Use it wisely.
The continuous monitoring philosophy
CGM represents a broader shift in healthcare philosophy — from episodic to continuous, from reactive to proactive: traditional healthcare is like checking the weather by looking out the window once per year (annual blood tests); CGM is like having a weather station on your roof (continuous real-time data). This shift — from snapshots to streams — is transforming how we understand metabolic health.
The same philosophical shift is occurring across medicine: continuous blood pressure monitoring (vs. annual office readings), continuous heart rhythm monitoring (Apple Watch, AliveCor — vs. annual EKGs), continuous sleep monitoring (Oura, WHOOP — vs. subjective sleep quality reports), and continuous activity monitoring (steps, calories, movement patterns — vs. self-reported exercise).
Together, these continuous data streams create a comprehensive real-time health picture that was impossible a decade ago. The question is no longer whether continuous monitoring is valuable — it is how to interpret, act on, and avoid being overwhelmed by the data.
The metabolic flexibility paradigm
One of the most important concepts CGM illuminates is "metabolic flexibility" — the body's ability to efficiently switch between fuel sources (glucose, fatty acids, ketones) based on availability and demand. Metabolically flexible individuals show: smaller glucose excursions after meals, faster return to baseline after eating, stable glucose during exercise (efficient fat oxidation), and stable overnight glucose (minimal dawn phenomenon).
Metabolic inflexibility — poor fuel-switching ability — is an early marker of metabolic disease and may precede insulin resistance by years. CGM can detect metabolic inflexibility before it appears on standard laboratory tests — making it a potential tool for very early metabolic disease prevention.
CGM and meal timing
CGM data has contributed to the growing evidence base for chrononutrition — the timing of food intake relative to circadian rhythms: glucose responses to identical meals are significantly larger in the evening than in the morning, late-night eating produces the largest glucose spikes and the slowest recovery, breakfast consumption within 1-2 hours of waking aligns with circadian insulin sensitivity, and time-restricted eating (limiting food intake to an 8-12 hour window) produces measurable improvements in glucose regulation.
These chrononutrition insights — visible through CGM — suggest that when you eat may be as important as what you eat.
CGM and mental health
An underreported application of CGM is its relevance to mental health: glucose variability — frequent spikes and crashes — is associated with mood instability, anxiety, and cognitive fog; hypoglycemic episodes (glucose <70 mg/dL) produce adrenaline release, anxiety, irritability, and panic-like symptoms; reactive hypoglycemia (a glucose crash 2-4 hours after a high-carbohydrate meal) may explain the "2:30 PM slump" that many people attribute to fatigue rather than metabolic dysfunction; and CGM can help individuals with mood disorders identify glucose patterns that trigger or worsen symptoms.
The connection between glucose stability and emotional stability is increasingly recognized in integrative psychiatry — and CGM provides the data to make this connection visible and actionable.
The social dimension of CGM
CGM use has social and psychological dimensions that extend beyond individual health: couples and families using CGM together often discover shared dietary triggers and develop healthier eating patterns collectively; social accountability (sharing glucose data with friends or coaching platforms) can strengthen dietary adherence; and the gamification of glucose data (points, streaks, challenges) leverages social motivation for behavior change.
However, social CGM use also carries risks: comparison with others' glucose responses can produce shame or anxiety, and the public display of metabolic data raises privacy concerns that are only beginning to be addressed.
The research frontier
Active CGM research in non-diabetic populations includes: whether CGM-guided dietary modification reduces Type 2 diabetes incidence (prospective RCTs underway), whether CGM feedback improves cardiovascular risk factors (HbA1c, triglycerides, waist circumference), whether CGM-based interventions are cost-effective compared to standard dietary counseling, optimal CGM wear duration for behavioral learning (2 weeks? 1 month? intermittent usage?), and whether CGM use in pregnancy can optimize gestational glucose management (even in non-gestational-diabetic women).
These studies will determine whether CGM transitions from a biohacker curiosity to a mainstream preventive health tool — or whether it remains a niche technology for the metabolically anxious and the data-curious.
The democratization of metabolic awareness
The most important contribution of consumer CGM may not be clinical — it may be cultural: making metabolic health visible. For decades, metabolic health has been invisible — reduced to annual fasting blood glucose tests that capture a single moment rather than the dynamic reality of glucose metabolism. CGM makes the invisible visible: the glucose spike after a bagel, the stabilization after a walk, the overnight dip, the stress response.
This visibility transforms metabolic health from an abstract concept to a lived experience. And lived experience drives behavior change more effectively than clinical recommendations. The patient who sees their glucose spike to 180 mg/dL after white rice — and sees it stay flat after cauliflower rice — is going to choose cauliflower rice. Not because a doctor told them to. Because they saw it with their own eyes, on their own body, in real time.
This democratization of metabolic awareness — regardless of whether it meets the clinical evidence bar for formal recommendation — may be CGM's most lasting contribution. Making invisible biology visible empowers patients in a way that abstract health advice never can. And empowered patients make better decisions. That is the promise of continuous glucose monitoring — and the future of personalized metabolic health.
CGM technology is the metabolic mirror — a tool that makes the invisible visible, that transforms abstract lab values into lived, felt, moment-by-moment experience. Use it wisely, use it with clinical guidance, and use it to build a relationship with your own metabolism that empowers better decisions for a lifetime.
The glucose trace tells a story — your story. Read it wisely.